ESOM新闻 //www.ultimamakeup.com/ ESOM最新消息 en-GB smo.org (Andrea Norsa) 2024年1月2日01114+0100 2024年1月2日01114+0100 eZ构件进化dev(http://ez构件s.org/docs/tuments/Feed) http://www.rssboard.org/rss-specification Mounetuzumab+PolatuzumabVedotin向递归复发或易碎性大B细胞Lymphome //www.ultimamakeup.com/oncology-news/mosunetuzumab-plus-polatuzumab-vedotin-shows-promise-for-patients-with-aggressive-relapsed-or-refractory-aggressive-large-b-cell-lymphoma

初级分析当前阶段Ib/II研究结果

 unreply@esmo.org ff44b8144566f29e3f91ecf3fdb64f43 Thu,2023年12月21日09:10:00+0100 等同NSCL可有效处理SBRT+护理标准,引向PFS增长 //www.ultimamakeup.com/oncology-news/oligoprogression-in-metastatic-nsclc-could-be-effectively-treated-with-sbrt-plus-standard-of-care-leading-to-increase-in-pfs-compared-with-standard-of-care-only

CURB研究发现

 unreply@esmo.org d4a361b3110f7003b37ef74554702f01 Thu,2023年12月21日 与Cetuximab组合Divarasib演示病人可管理安全简介和有希望活动与KRASG12C阳性CRC //www.ultimamakeup.com/oncology-news/divarasib-in-combination-with-cetuximab-demonstrates-a-manageable-safety-profile-and-promising-activity-in-patients-with-kras-g12c-positive-crc

剖析癌症患者发现 包含C臂Ib研究

 unreply@esmo.org 376a0aa23f1b50ef7cdd3fef5531b3e5 2023年12月20日wed Osimertinib显示前非处理病人有希望活动 //www.ultimamakeup.com/oncology-news/osimertinib-shows-promising-activity-in-previously-untreated-patients-with-metastatic-nsclc-harbouring-uncommon-egfr-mutations-other-than-the-exon-20-insertion

UNICORN研究发现

 unreply@esmo.org f88220bf2a737916cd3164ffaff23122 2023年12月19日9:00+0100 mirveuximabSoravtansine-gynx显示白金-Rese //www.ultimamakeup.com/oncology-news/mirvetuximab-soravtansine-gynx-shows-a-significant-benefit-over-chemotherapy-in-women-with-platinum-resistant-fra-positive-ovarian-cancer

MIRASOL研究发现

 unreply@esmo.org 41dfb6481c55e5509d0f47d1f85a586d 2023年12月18日Mon上午9:00+0100 FDA核准非计量立体敏感前列腺癌与生化复发 //www.ultimamakeup.com/oncology-news/fda-approves-enzalutamide-for-non-metastatic-castration-sensitive-prostate-cancer-with-biochemical-recurrence

效果证据基于EMBARK研究的结果

 unreply@esmo.org f95c211be31143beab970b252864692c 弗里2023年12月15日9:00+0100 药管局批准Pembromizumab与Chemo理疗 //www.ultimamakeup.com/oncology-news/fda-approves-pembrolizumab-with-chemotherapy-for-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma

有效性证据基础为KEYNOTE-859研究结果

 unreply@esmo.org 89c335c1a45279c0a42b7fedf441c92c Thu,2023年12月14日 Talazoparib+Enzaluta //www.ultimamakeup.com/oncology-news/talazoparib-plus-enzalutamide-improves-rpfs-in-first-line-treatment-for-patients-with-mcrpc-harbouring-hrr-gene-alterations

TALAPRO-2研究发现

 unreply@esmo.org 9c48914bb137379ac77a290134e96f96 wed2023年12月13日 9:00+0100 Atesolizumab添加第一线Bevacizumab+Platinum系统改善患代谢性、持久性或复发子宫癌患者生存 //www.ultimamakeup.com/oncology-news/adding-atezolizumab-to-first-line-bevacizumab-plus-platinum-regimen-improves-survival-in-patients-with-metastatic-persistent-or-recurrent-cervical-cancer

ENGT-Cx10-GEICO68-C-JGOG1084-GOG-3030研究发现

 unreply@esmo.org 34ba130e5c13c2918ca281871c6bb6af 2023年12月12日9:00+0100 Imetstat显示持久传递自主和疾病调控活动 //www.ultimamakeup.com/oncology-news/imetelstat-shows-durable-transfusion-independence-and-disease-modifying-activity-in-heavily-transfused-patients-with-lower-risk-mds-who-are-not-responding-to-or-are-ineligible-for-esa

IMERGE研究发现

 unreply@esmo.org 05db13b1e1f1ffc9732ea5fa8c0dfd02 2023年12月11日Mon-9:00+0100 FDA批准Nirogacestatd //www.ultimamakeup.com/oncology-news/fda-approves-nirogacestat-for-desmoid-tumours

效果证据基础 DeFi研究的结果

 unreply@esmo.org c1cef936135f4f0b67cff59ba566e173 Thu, 072023 11: 00+0100 EMA推荐授权Trametinib处理低高级Glioma //www.ultimamakeup.com/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-trametinib-for-the-treatment-of-low-and-high-grade-glioma

接受正面意见治疗一岁或以上病人

 unreply@esmo.org 116ebe439103ab8de599286a62c6ebd4 Thu, 072023 10: 00+0100 软性组合Panitumab结果LongerPFS与Chemorforic KRASG12C变换mCRC //www.ultimamakeup.com/oncology-news/sotorasib-in-combination-with-panitumumab-results-in-longer-pfs-in-patients-with-chemorefractory-kras-g12c-mutated-mcrc

codeBreaK300研究发现

 noreply@esmo.org 7faf2f0f370e1788fe5582db9e13a385 wed2023年12月6日 Neoadjivant Toripalimab和Axitinib //www.ultimamakeup.com/oncology-news/neoadjuvant-toripalimab-combined-with-axitinib-demonstrates-a-promising-pathologic-response-rate-in-resectable-mucosal-melanoma

第二阶段研究发现

 unreply@esmo.org 48c5eec9dd1de5913047b1c48bb2d392 2023年5月9: 00+0100 首项研究证明PD1Imune检验屏蔽 //www.ultimamakeup.com/oncology-news/first-study-to-demonstrate-that-pd1-immune-checkpoint-blockade-may-yield-clinical-pathologic-regression-in-some-patients-with-high-risk-oral-precancerous-disease

二级非随机控制研究结果

 unreply@esmo.org 2b40d4bdb5a1445dd0a7291fa1432693 2023年12月4日Mon.00:00+0100 EMA推荐向高级二元轨迹癌患者扩展Pembroizumab标识 //www.ultimamakeup.com/oncology-news/ema-recommends-extending-indications-for-pembrolizumab-to-patients-with-advanced-biliary-tract-carcinoma

新指针与精品和芯片并用一线处理

 unreply@esmo.org cdc94320f2f82b09e41cfafc746cf60b 弗里2023年12月01日9:00+0100 FDA修正Pembroizumab局部高级不可解析或MetisticHER2阳性气态癌症患者一线处理 //www.ultimamakeup.com/oncology-news/fda-amends-indication-for-pembrolizumab-in-the-first-line-treatment-for-patients-with-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-cancer

更新标识限制肿瘤表示PD-L1CPS##I

 esmo.org (Ivan Lovretic (Netgen)) 0a56d05b3f8749810d9573e006255829 Thu,2023年11月30日 EMPOIMMUNO-Oncology大会2023年12月6日至8日 //www.ultimamakeup.com/newsroom/press-and-media-hub/esmo-media-releases/esmo-immuno-oncology-congress-2023-6-8-december-2023-geneva-switzerland

ESBOIMMUNO-Ocnology大会2023年12月6-8日将在瑞士日内瓦举行,专家讨论快速运动癌症治疗领域的最新科学发展,并配有虚拟组件

 noreply@esmo.org 82fb1a7b6ac7d4cce927d50a6c02963f 2023年11月29日Wed中午2:00+0100 Osimertinib+Pemexed和Platinum代理与EGFR改编高级NSCL //www.ultimamakeup.com/oncology-news/a-combination-of-osimertinib-plus-pemetrexed-and-a-platinum-based-agent-significantly-improves-pfs-in-first-line-treatment-of-patients-with-egfr-mutated-advanced-nsclc

FLAURA2研究发现

 unreply@esmo.org 0adc2c44a26f3aa50f6d292ea6e31091 wed2023年11月29日9:00+0100 Rituximab支持入院后MRD负作用 //www.ultimamakeup.com/oncology-news/efficacy-of-rituximab-maintenance-in-patients-with-mantle-cell-lymphoma-who-are-mrd-negative-after-induction

Europe MCL老年人研究发现

 unreply@esmo.org bd1e10e0ff61d32ccaaa326827f62162 2023年11月28日 9:00+0100